Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Uniqure NV QURE

Healthcare Biotechnology
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.


NDAQ:QURE - Post by User

Uniqure NV
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(227)
•••
Post by whytestockson Jul 09, 2024 1:15pm
48 Views
Post# 36124656

uniQure N.V. (NASDAQ: QURE) Near the Top of Equities by Perc

uniQure N.V. (NASDAQ: QURE) Near the Top of Equities by Perc
BREAKING NEWS: $QURE uniQure N.V. (NASDAQ: QURE) Near the Top of Equities by Percentage Gain on 7/9uniQure N.V. (NASDAQ: QURE) is one of today's top gainers. The company's shares have moved 71.69% on the day to $6.49. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranaco...QURE - uniQure N.V. (NASDAQ: QURE) Near the Top of Equities by Percentage Gain on 7/9

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities